ArticleThe Journal of infectious diseases2026
Cross-reactive H5N1 Neuraminidase Antibodies by Age and Influenza A Imprinting Cohorts of the Past Century: Population-Based Serosurvey, British Columbia, Canada.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Population Immunity to Influenza Neuraminidase: From Immune Imprinting to Pandemic Preparedness.Vaccines · 2026Review
- Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies.mBio · 2026Article
- Cross-reactive human antibody responses to H9N2 influenza virus, New York, United States, 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Avian influenza overview December 2025-February 2026.EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPreexisting immunity to emerging influenza viruses informs pandemic risk assessment. We compared cross-reactive neuraminidase antibody levels against avian influenza A(H5N1) by age and birth (imprinting) cohorts defined by periods of human influenza A subtype (H1N1, H2N2, or H3N2) circulation over the past century.
methodsWe used anonymized residual sera collected from 10 age groups spanning 1 to >80 years during an August 2024 cross-sectional serosurvey conducted in British Columbia, Canada. We assessed neuraminidase inhibition antibody titers by enzyme-linked lectin assay against clade 2.3.4.4b H5N1 and 2009-H1N1pdm09 and 1968 H3N2 pandemic strains.
resultsAmong 575 participants with a median age of 32 years (IQR, 15-62), 404 (70%) had detectable anti-N1 titers ≥10 against H5N1, with 260 (45%), 182 (32%), and 98 (17%) having titers ≥40, ≥80, and ≥160, respectively. Anti-N1 titers against 2009-H1N1pdm09 and H5N1 were strongly correlated (r = 0.86; 95% CI, .82-.89): highest among young adults born 1997 to 2003 who were school-aged children during the 2009 H1N1 pandemic (427.9, 100.8); lowest among the least influenza-experienced pediatric cohorts born 2015 to 2023 (20.7, 6.8) and middle-aged adults born during the 1957-1967 H2N2 era (25.1, 10.7); increasing toward a similar secondary peak among the oldest cohorts born during the pre-1947 H1N1 era (387.3, 81.0).
conclusionsA substantial proportion of the population has preexisting anti-N1 against H5N1, with age-related variation reflecting H1N1 imprinting and exposure opportunities. Through heightened attack rates and shifts in immunologic hierarchies, historical pandemics shape and expand the immune repertoire influencing potential preimmunity to emerging zoonotic threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.